Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Trial Profile

An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Registrational
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
    • 07 Aug 2019 According to a Cara Therapeutics media release, this trial is expected to support worldwide registration filings of KORSUVA Injection.
    • 07 Aug 2019 According to a Cara Therapeutics media release, approximately 165 patients having completed at least 6 months of treatment and over 50% of these patients having completed 1 year of treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top